Legalize59765 laws
59765 laws
- § 2353. Imposition of sanctions with respect to fentanyl trafficking by transnational criminal organizations
- § 2354. Penalties; waivers; exceptions
- § 2355. Treatment of forfeited property of transnational criminal organizations
- § 2361. Treatment of transnational criminal organizations in suspicious transactions reports of the Financial Crimes Enforcement Network
- § 2371. Exception relating to importation of goods
- § 2401. Definitions
- § 343a. Repealed. [Pub. L. 106–554, § 1(a)(1) [title V, § 517]](/us/pl/106/554/s1/a/1/tV/s517), Dec. 21, 2000, [114 Stat. 2763](/us/stat/114/2763), 2763A–73
- § 343–1. National uniform nutrition labeling
- § 343–2. Dietary supplement labeling exemptions
- § 343–3. Disclosure
- § 344. Emergency permit control
- § 345. Regulations making exemptions
- § 346. Tolerances for poisonous or deleterious substances in food; regulations
- § 346a. Tolerances and exemptions for pesticide chemical residues
- § 346b. Authorization of appropriations
- § 347. Intrastate sales of colored oleomargarine
- § 347a. Congressional declaration of policy regarding oleomargarine sales
- § 351. Adulterated drugs and devices
- § 352. Misbranded drugs and devices
- § 353. Exemptions and consideration for certain drugs, devices, and biological products
- § 353a. Pharmacy compounding
- § 353a–1. Enhanced communication
- § 353b. Outsourcing facilities
- § 353c. Prereview of television advertisements
- § 353d. Process to update labeling for certain generic drugs
- § 354. Veterinary feed directive drugs
- § 1479. Advancement of funds, property, or services by foreign governments; disposition; availability; return of unexpended balances or property
- § 355–1. Risk evaluation and mitigation strategies
- § 356. Expedited approval of drugs for serious or life-threatening diseases or conditions
- § 356b. Reports of postmarketing studies
- § 356c. Discontinuance or interruption in the production of life-saving drugs
- § 356c–1. Annual reporting on drug shortages
- § 356d. Coordination; task force and strategic plan
- § 356e. Drug shortage list
- § 356f. Hospital repackaging of drugs in shortage
- § 360bbb–5. Critical Path Public-Private Partnerships
- § 360bbb–5a. Emerging technology program
- § 360bbb–6. Risk communication
- § 360bbb–7. Notification
- § 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
- § 360bbb–8a. Optimizing global clinical trials
- § 360bbb–8b. Use of clinical investigation data from outside the United States
- § 360bbb–8c. Patient participation in medical product discussion
- § 360bbb–8d. Notification, nondistribution, and recall of controlled substances
- § 360b–1. Priority zoonotic animal drugs
- § 360c. Classification of devices intended for human use
- § 360cc. Protection for drugs for rare diseases or conditions
- § 360ccc. Conditional approval of new animal drugs for minor use and minor species and certain new animal drugs
- § 360ccc–1. Index of legally marketed unapproved new animal drugs for minor species
- § 5113. Information and services